Medallion Financial Corp. (MFIN) Latest News

NASDAQ Currency in USD Disclaimer

Add to Alerts ADD TO LIST

$9.58

north_east $0.17 (1.81%)

Day's range

$9.35

$9.66

Latest News of MFIN

FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer

FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer

By Yahoo! Finance | 2 weeks ago

Medallion Financial Corp.'s (NASDAQ:MFIN) top owners are individual investors with 48% stake, while 31% is held by institutions

Medallion Financial Corp.'s (NASDAQ:MFIN) top owners are individual investors with 48% stake, while 31% is held by institutions

By Yahoo! Finance | 3 months ago

FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer

FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer

By Yahoo! Finance | 4 months ago

Medallion Financial (NASDAQ:MFIN) delivers shareholders notable 8.7% CAGR over 5 years, surging 23% in the last week alone

Medallion Financial (NASDAQ:MFIN) delivers shareholders notable 8.7% CAGR over 5 years, surging 23% in the last week alone

By Yahoo! Finance | 5 months ago

AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study

AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study

By Yahoo! Finance | 6 months ago